Amylyx stock drops over 3% due to trial uncertainty despite better-than-expected earnings

LootboxPhobia · 2026-03-03T12:24:26+00:00

Amylyx Pharmaceuticals announced that its fourth-quarter results exceeded expectations, with a loss of $0.30 per share. The company completed recruitment for the hypoglycemia trial following avexitide weight-loss surgery, with data expected to be released in 2026 and aiming for a 2027上市. The company's cash reserves are expected to last until 2028.

LootboxPhobia

2026-03-03 12:24:26

Abstract generation in progress

Cambridge, Massachusetts - On Tuesday, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced fourth-quarter results that exceeded analyst expectations.

Following the earnings release, the company’s stock fell 3.59% in pre-market trading as investors weighed the company’s commercialization prospects.

The company reported a fourth-quarter loss of $0.30 per share, better than the analyst consensus of a $0.34 loss per share. Revenue data for the quarter was not disclosed. For the full fiscal year 2025, Amylyx reported a net loss of $1.53 per share, compared to a $4.43 loss per share in 2024.

Amylyx announced that recruitment for its pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia (PBH) has been completed.

The company expects to randomize and dose the final eligible participants this month, with topline data anticipated in the third quarter of 2026. If approved, commercialization is targeted for 2027.

Co-CEOs Joshua Cohen and Justin Klee stated, “2025 is a significant year for Amylyx’s key avexitide program for post-bariatric hypoglycemia, and our broader pipeline has also made progress. With the completion of LUCIDITY recruitment, we expect to finish enrollment this month and continue to anticipate topline data in the third quarter of 2026.”

Research and development expenses for the fourth quarter decreased from $22.9 million last year to $21.2 million, primarily due to reduced spending on the ALS and PSP treatment AMX0035, partially offset by increased clinical development costs for avexitide.

Selling, general, and administrative expenses declined year-over-year from $17.1 million to $15.4 million.

As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments of $317 million, down from $344 million as of September 30, 2025. Amylyx expects its cash reserves to last through 2028, sufficient to support operations until potential commercialization of avexitide.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.